Filtered By:
Drug: Rituxan
This page shows you your search results in order of relevance. This is page number 14.
Order by Relevance | Date
Total 7090 results found since Jan 2013.
Primary Central Nervous System Lymphoma in a Patient with Down Syndrome
We report our experience with a patient with Down syndrome in whom PCNSL was diagnosed. The patient, a 48-year-old man with a diagnosis of Down syndrome, had no history of malignant tumors. The patient visited the hospital with complaints of left hemiparesis and gait disturbance. A thorough examination revealed the brain tumors, and tumor biopsy confirmed the diagnosis of PCNSL. The final pathological diagnosis was diffuse large B-cell lymphoma of the central nervous system. Chemotherapy with rituximab, methotrexate, procarbazine, and vincristine was administered, and whole-brain irradiation was planned in conjunction with...
Source: Journal of Nippon Medical School - June 1, 2022 Category: Universities & Medical Training Authors: Ami Shibata Fumio Yamaguchi Kazuma Sasaki Shoji Yokobori Akio Morita Source Type: research
Severe eosinophilic granulomatosis with polyangiitis responding to a combination of rituximab and mepolizumab
Am J Med Sci. 2022 Aug 12:S0002-9629(22)00331-7. doi: 10.1016/j.amjms.2022.07.007. Online ahead of print.ABSTRACTEosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss Syndrome, is a multisystem antineutrophil cytoplasmic antibody (ANCA) positive vasculitis, characterized by the presence of chronic rhinosinusitis, asthma and prominent peripheral blood eosinophilia. Although the most commonly involved organ is the lung, followed by the skin, EGPA can affect any organ system. Herein, we present the complicated case of an 18-year-old male patient with severe life-threatening EGPA, with central n...
Source: The American Journal of the Medical Sciences - August 15, 2022 Category: General Medicine Authors: Georgios Tsioulos Dimitris Kounatidis Natalia G Vallianou Nektarios Koufopoulos Pelagia Katsimbri Anastasia Antoniadou Source Type: research
Transplant outcomes of 100 cases of living-donor ABO-incompatible kidney transplantation
CONCLUSIONS: An individualized preconditioning regimen can achieve comparable graft and patient survival rates in ABOi KT with ABOc KT. Rit-free preconditioning effectively prevented AR without increasing the risk of infectious events in those with lower initial titers; however, antibody titer rebound should be monitored.PMID:36103981 | DOI:10.1097/CM9.0000000000002138
Source: Chinese Medical Journal - September 14, 2022 Category: General Medicine Authors: Saifu Yin Qiling Tan Youmin Yang Fan Zhang Turun Song Yu Fan Zhongli Huang Tao Lin Xianding Wang Source Type: research
Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & amp; consequences
Indian J Med Res. 2022 Mar&Apr;155(3&4):335-346. doi: 10.4103/ijmr.IJMR_312_19.ABSTRACTThe utilization of the monoclonal antibodies (mAbs) as therapeutic agents is one of the most favourable fields in immunotherapy. The immunogenicity of mAbs is one of the major parameters that may restrict their therapeutic and diagnostic applications. Rituximab, a chimeric mAb against CD20, is attached to the B-cell membrane-linked CD20 and is used to treat some B-cell-related malignancies, a number of autoantibody-mediated autoimmune disorders and improvement of graft survival. The risk of anti-rituximab antibody (ARA) development and A...
Source: The Indian Journal of Medical Research - September 20, 2022 Category: Biomedical Science Authors: Fatemeh Saffari Abdollah Jafarzadeh Source Type: research
